Anti-tumor Drug Market 2018 Global Analysis By key Players – Roche, Novartis, Celgene, Bristol-Myers Squibb, Amgen

Anti-tumor Drug Market 2018

Wiseguyreports.Com adds “Anti-tumor Drug Market –Market Demand, Growth, Opportunities, Analysis of Top Key Players and Forecast to 2025” To Its Research Database.

Report Details:

This report provides in depth study of “Anti-tumor Drug Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Anti-tumor Drug Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization.

This report studies the global Anti-tumor Drug market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Anti-tumor Drug market by companies, region, type and end-use industry.

Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era. 

In China, antitumor drugs are also the key areas of concern for many enterprises. Such as Jiangsu Hengrui, Qilu Pharmaceutical and other well-known domestic enterprises in the anti-tumor drugs have invested a lot of money, there are many innovative anti-cancer drugs into the clinical research stage. In the meantime, there has been "explosive" growth in the development of molecularly targeted drugs, with at least hundreds of drugs under development, and it is conceivable that the market will be quite crowded in the next five to 10 years. Therefore, domestic enterprises should fully understand the feasibility of the project and the fierce market competition that they may face in the future. 

China's bio-pharmaceutical industry already has a good foundation; from the national level to local governments at all levels continue to step up efforts to support the development of bio-pharmaceutical industry. The output value of the pharmaceutical industry maintained a growth rate of 20% during the 12th Five-Year Plan period. In 2013, the total output value of the pharmaceutical industry reached 2.1 trillion yuan. However, compared with the bio-pharmaceutical industry in the advanced countries in the world, there is still a huge gap between the biomedical industry in our country and the demand for building an overall well-to-do society. Mainly manifested in: small-scale enterprises, more than 10 billion yuan enterprises and more than one billion yuan less; independent innovation ability is weak, many varieties of imitation with independent intellectual property rights of the few species; restrict some of the long-term development of biomedical industry , Deep-seated problems still exist. 

This report focuses on the global top players, covered 
Roche 
Novartis 
Celgene 
Bristol-Myers Squibb 
Amgen 
Johnson & Johnson 
Pfizer 
Takeda 
Eli Lilly 
AstraZeneca 
Astellas 
Merck & Co 
Sanofi 
Bayer 
Biogen Idec 
Eisai 
Teva 
Otsuka

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/3267433-global-anti-tumor-drug-market-size-status-and-forecast-2025

Market segment by Regions/Countries, this report covers 
United States 
Europe 
China 
Japan 
Southeast Asia 
India

Market segment by Type, the product can be split into 
Cytotoxic Drugs 
Non-cytotoxic Drugs

Market segment by Application, split into 
Alkylating Agents 
Anti-metabolism Drugs 
Platinum Antineoplastic Agents 
Anthracycline antitumor drugs 
Microtubule Stabilizer 
Endocrine Therapy Drugs 
Immunotherapy Drugs 
Gene Therapy Drugs 
Targeted Antineoplastic Drugs

Key Stakeholders 
Anti-tumor Drug Manufacturers 
Anti-tumor Drug Distributors/Traders/Wholesalers 
Anti-tumor Drug Subcomponent Manufacturers 
Industry Association 
Downstream Vendors

If you have any special requirements, please let us know and we will offer you the report as you want.

Complete Report Details@ https://www.wiseguyreports.com/reports/3267433-global-anti-tumor-drug-market-size-status-and-forecast-2025

Major Key Points in Table of Content:

Global Anti-tumor Drug Market Size, Status and Forecast 2025 
1 Industry Overview of Anti-tumor Drug 
1.1 Anti-tumor Drug Market Overview 
1.1.1 Anti-tumor Drug Product Scope 
1.1.2 Market Status and Outlook 
1.2 Global Anti-tumor Drug Market Size and Analysis by Regions (2013-2018) 
1.2.1 United States 
1.2.2 Europe 
1.2.3 China 
1.2.4 Japan 
1.2.5 Southeast Asia 
1.2.6 India 
1.3 Anti-tumor Drug Market by Type 
1.3.1 Cytotoxic Drugs 
1.3.2 Non-cytotoxic Drugs 
1.4 Anti-tumor Drug Market by End Users/Application 
1.4.1 Alkylating Agents 
1.4.2 Anti-metabolism Drugs 
1.4.3 Platinum Antineoplastic Agents 
1.4.4 Anthracycline antitumor drugs 
1.4.5 Microtubule Stabilizer 
1.4.6 Endocrine Therapy Drugs 
1.4.7 Immunotherapy Drugs 
1.4.8 Gene Therapy Drugs 
1.4.9 Targeted Antineoplastic Drugs

2 Global Anti-tumor Drug Competition Analysis by Players 
2.1 Anti-tumor Drug Market Size (Value) by Players (2013-2018) 
2.2 Competitive Status and Trend 
2.2.1 Market Concentration Rate 
2.2.2 Product/Service Differences 
2.2.3 New Entrants 
2.2.4 The Technology Trends in Future

3 Company (Top Players) Profiles 
3.1 Roche 
3.1.1 Company Profile 
3.1.2 Main Business/Business Overview 
3.1.3 Products, Services and Solutions 
3.1.4 Anti-tumor Drug Revenue (Million USD) (2013-2018) 
3.2 Novartis 
3.2.1 Company Profile 
3.2.2 Main Business/Business Overview 
3.2.3 Products, Services and Solutions 
3.2.4 Anti-tumor Drug Revenue (Million USD) (2013-2018) 
3.3 Celgene 
3.3.1 Company Profile 
3.3.2 Main Business/Business Overview 
3.3.3 Products, Services and Solutions 
3.3.4 Anti-tumor Drug Revenue (Million USD) (2013-2018) 
3.4 Bristol-Myers Squibb 
3.4.1 Company Profile 
3.4.2 Main Business/Business Overview 
3.4.3 Products, Services and Solutions 
3.4.4 Anti-tumor Drug Revenue (Million USD) (2013-2018) 
3.5 Amgen 
3.5.1 Company Profile 
3.5.2 Main Business/Business Overview 
3.5.3 Products, Services and Solutions 
3.5.4 Anti-tumor Drug Revenue (Million USD) (2013-2018) 
3.6 Johnson & Johnson 
3.6.1 Company Profile 
3.6.2 Main Business/Business Overview 
3.6.3 Products, Services and Solutions 
3.6.4 Anti-tumor Drug Revenue (Million USD) (2013-2018) 
3.7 Pfizer 
3.7.1 Company Profile 
3.7.2 Main Business/Business Overview 
3.7.3 Products, Services and Solutions 
3.7.4 Anti-tumor Drug Revenue (Million USD) (2013-2018) 
3.8 Takeda 
3.8.1 Company Profile 
3.8.2 Main Business/Business Overview 
3.8.3 Products, Services and Solutions 
3.8.4 Anti-tumor Drug Revenue (Million USD) (2013-2018) 
3.9 Eli Lilly 
3.9.1 Company Profile 
3.9.2 Main Business/Business Overview 
3.9.3 Products, Services and Solutions 
3.9.4 Anti-tumor Drug Revenue (Million USD) (2013-2018) 
3.10 AstraZeneca 
3.10.1 Company Profile 
3.10.2 Main Business/Business Overview 
3.10.3 Products, Services and Solutions 
3.10.4 Anti-tumor Drug Revenue (Million USD) (2013-2018) 

Continued….

Contact Us:

NORAH TRENT               

Ph: +1-646-845-9349 (US)  

Sales@Wiseguyreports.Com

Ph: +44 208 133 9349 (UK)

ABOUT US:

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

ADDRESS:

WISE GUY RESEARCH CONSULTANTS PVT LTD
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar
Pune - 411028
Maharashtra, India

This release was published on openPR.